Clinical Trial Detail

NCT ID NCT03479268
Title Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors OHSU Knight Cancer Institute
Indications

CLL/SLL

chronic lymphocytic leukemia

prolymphocytic leukemia

lymphoplasmacytic lymphoma

marginal zone B-cell lymphoma

diffuse large B-cell lymphoma

follicular lymphoma

mantle cell lymphoma

Therapies

Ibrutinib + MLN4924

Age Groups: adult senior

No variant requirements are available.